Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zonisamide Clear all
Terminated Phase 2 Interventional

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
zonisamide SR plus olanzapine, Placebo plus olanzapine
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
National City, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Sep 4, 2026, 7:42 PM EDT
Withdrawn Phase 4 Interventional

Zonisamide for Fibromyalgia & Migraine

NCT00259636
View directory record Official record
Conditions
Fibromyalgia, Migraine
Interventions
zonisamide
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Sep 4, 2026, 7:42 PM EDT
Withdrawn Not applicable Interventional

Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

NCT00777218
View directory record Official record
Conditions
Migraine
Interventions
propranolol, zonisamide, topiramate
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence

NCT01847469
View directory record Official record
Conditions
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Interventions
Enhanced-Cognitive Processing Therapy-C (E-CPT-C), Zonisamide, Placebo
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

NCT01161979
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide, Zonegran
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Sep 4, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional Results available

Zonisamide for Heavy Drinkers With Bipolar Disorder

NCT01566370
View directory record Official record
Conditions
Alcohol Use Disorders, Bipolar Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

A Safety/Efficacy Trial of Zonisamide for Essential Tremor

NCT00223743
View directory record Official record
Conditions
Essential Tremor
Interventions
Zonisamide
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

NCT00339014
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide CR and Bupropion SR, Placebo
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 4, 2026, 7:42 PM EDT
Terminated Phase 4 Interventional

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

NCT02727101
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 4, 2026, 7:42 PM EDT
Not yet recruiting Phase 4 Interventional

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

NCT06534502
View directory record Official record
Conditions
Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
Interventions
Zonisamide Oral Product
Drug
Lead sponsor
Azurity Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

NCT00401973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorders
Interventions
olanzapine, amantadine, metformin, zonisamide, Wellness education
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
National City, California • Canton, Ohio • Johnson City, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2009 · Synced Sep 4, 2026, 7:42 PM EDT
Terminated Phase 3 Interventional Results available

Effectiveness of Zonisamide in Alcohol Dependent Veterans

NCT02368431
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 4, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional Results available

Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

NCT00862563
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Alcohol Abuse
Interventions
Topiramate, Zonisamide, Levetiracetam, Sugar Pill
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 4, 2026, 7:42 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

NCT05134857
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol Self Administration Laboratory

NCT00398918
View directory record Official record
Conditions
Alcoholism
Interventions
zonisamide, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

NCT00404248
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
terameprocol, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

NCT00650052
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide Capsules 100 mg, Zonegran® Capsules 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

NCT02900352
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

NCT00649714
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide Capsules 100 mg, Zonegran® Capsules 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 4, 2026, 7:42 PM EDT
Completed Phase 4 Interventional

Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial

NCT00203450
View directory record Official record
Conditions
Obesity
Interventions
Zonegran, Placebo
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 4, 2026, 7:42 PM EDT